FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $36.34, for a total transaction of $1,440,372.24. Following the completion of the sale, the chief executive officer now owns 2,527,044 shares of the company’s stock, valued at approximately $91,832,778.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of FGEN opened at $37.32 on Friday. FibroGen Inc has a 12 month low of $33.51 and a 12 month high of $68.55. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.71%. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. During the same quarter in the prior year, the business posted ($0.50) EPS. FibroGen’s quarterly revenue was down 25.1% on a year-over-year basis. As a group, equities research analysts forecast that FibroGen Inc will post -0.9 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in FGEN. Lindbrook Capital LLC increased its stake in shares of FibroGen by 150.0% during the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 300 shares during the last quarter. FTB Advisors Inc. acquired a new position in shares of FibroGen during the 1st quarter worth $27,000. Meeder Asset Management Inc. increased its stake in shares of FibroGen by 622.4% during the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 529 shares during the last quarter. Intercontinental Wealth Advisors LLC acquired a new position in shares of FibroGen during the 4th quarter worth $37,000. Finally, Manchester Capital Management LLC acquired a new position in shares of FibroGen during the 1st quarter worth $39,000. Institutional investors own 66.31% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of FibroGen in a research report on Monday, February 11th. They issued a “buy” rating and a $71.00 target price for the company. ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 14th. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 22nd. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c-” rating in a research note on Friday, March 29th. Finally, Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. FibroGen currently has a consensus rating of “Hold” and a consensus target price of $68.50.

TRADEMARK VIOLATION WARNING: “FibroGen Inc (FGEN) CEO Thomas B. Neff Sells 39,636 Shares” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/fibrogen-inc-fgen-ceo-thomas-b-neff-sells-39636-shares/3013053.html.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: What is the Book Value of a Share?

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.